Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.05 (-5.24%)
Close on Nov 13, 2026Market cap $280.72MP/E –Yield –
Ocugen profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Ocugen's profit margin for the twelve months ending Sep 30, 2025 was -1192.2%. For fiscal 2025 it was -1537.4%, against -1333.0% the year before. The highest annual figure on record is -1045.0% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1537.4% | −204.4 |
| FY2024 | Dec 31, 2024 | -1333.0% | −288.0 |
| FY2023 | Dec 31, 2023 | -1045.0% | +2443.9 |
| FY2022 | Dec 31, 2022 | -3488.9% | +47259.9 |
| FY2020 | Dec 31, 2020 | -50748.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -184.4% | +889.1 |
| Q2 FY2026 | Jun 30, 2026 | -1671.8% | −635.4 |
| Q1 FY2026 | Mar 31, 2026 | -1250.9% | +565.8 |
| Q3 FY2025 | Sep 30, 2025 | -1144.5% | −2.7 |
| Q2 FY2025 | Jun 30, 2025 | -1073.5% | +265.7 |
| Q1 FY2025 | Mar 31, 2025 | -1036.5% | +139.5 |
| Q4 FY2024 | Dec 31, 2024 | -1816.8% | −1038.2 |
| Q3 FY2024 | Sep 30, 2024 | -1141.7% | −825.0 |
| Q2 FY2024 | Jun 30, 2024 | -1339.2% | +3416.5 |
| Q1 FY2024 | Mar 31, 2024 | -1175.9% | +2735.1 |
| Q4 FY2023 | Dec 31, 2023 | -778.6% | +1769.1 |
| Q3 FY2023 | Sep 30, 2023 | -316.8% | +4814.8 |
| Q2 FY2023 | Jun 30, 2023 | -4755.7% | −1414.8 |
| Q1 FY2023 | Mar 31, 2023 | -3911.1% | −108.1 |
| Q4 FY2022 | Dec 31, 2022 | -2547.7% | +5857.0 |
| Q3 FY2022 | Sep 30, 2022 | -5131.5% | – |
| Q2 FY2022 | Jun 30, 2022 | -3340.9% | – |
| Q1 FY2022 | Mar 31, 2022 | -3803.0% | – |
| Q2 FY2020 | Jun 30, 2020 | -8404.7% | – |
See a number that looks wrong?